(ATYR) aTyr Pharma - Overview
Stock: Efzofitimod, ATYR0101, ATYR0750
| Risk 5d forecast | |
|---|---|
| Volatility | 104% |
| Relative Tail Risk | -14.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.10 |
| Alpha | -92.72 |
| Character TTM | |
|---|---|
| Beta | 0.990 |
| Beta Downside | 1.219 |
| Drawdowns 3y | |
|---|---|
| Max DD | 90.15% |
| CAGR/Max DD | -0.29 |
Description: ATYR aTyr Pharma December 27, 2025
aTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotech that leverages tRNA-synthetase biology to create anti-fibrotic and anti-inflammatory therapies, primarily targeting pulmonary diseases in the United States.
Its lead asset, efzofitimod-a selective NRP2 modulator-is in a pivotal Phase 3 trial for pulmonary sarcoidosis and a Phase 1b/2a study for other interstitial lung diseases (ILDs) such as chronic hypersensitivity pneumonitis and connective-tissue-disease-related ILD. The company expects topline Phase 3 data by late 2025, a timeline that will be a key catalyst for valuation.
In addition, aTyr is advancing ATYR0101 (a fusion protein derived from aspartyl-tRNA synthetase) in preclinical work for systemic fibrosis, and ATYR0750 (an alanyl-tRNA synthetase domain) for liver disorders. A licensing partnership with Japan’s Kyorin Pharmaceutical covers development and commercialization of efzofitimod for ILDs in the Japanese market.
As of the latest 10-Q, aTyr reported $115 million of cash and marketable securities, giving it roughly 12-month runway at its current burn (~$30 million per quarter). The broader biotech sector is benefitting from rising prevalence of chronic lung diseases and increasing payer willingness to reimburse targeted biologics, which could amplify demand for successful ILD therapies.
For a deeper dive into how aTyr’s pipeline and financial outlook compare with peers, you might find ValueRay’s analyst notes useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -75.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.59 > 0.02 and ΔFCF/TA 14.18 > 1.0 |
| NWC/Revenue: 40.7k% < 20% (prev 26.5k%; Δ 14.2k% < -1%) |
| CFO/TA -0.59 > 3% & CFO -62.9m > Net Income -75.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.2m) vs 12m ago 28.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.19% > 50% (prev 0.26%; Δ -0.06% > 0%) |
| Interest Coverage Ratio: -30.75 > 6 (EBITDA TTM -76.5m / Interest Expense TTM -2.52m) |
Altman Z'' -15.00
| A: 0.73 (Total Current Assets 93.0m - Total Current Liabilities 15.7m) / Total Assets 106.7m |
| B: -5.55 (Retained Earnings -592.2m / Total Assets 106.7m) |
| C: -0.78 (EBIT TTM -77.7m / Avg Total Assets 99.1m) |
| D: -22.25 (Book Value of Equity -592.1m / Total Liabilities 26.6m) |
| Altman-Z'' Score: -41.97 = D |
Beneish M -3.64
| DSRI: 0.70 (Receivables 1.04m/1.83m, Revenue 190.0k/235.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.80 (AQ_t 0.03 / AQ_t-1 0.03) |
| SGI: 0.81 (Revenue 190.0k / 235.0k) |
| TATA: -0.11 (NI -75.1m - CFO -62.9m) / TA 106.7m) |
| Beneish M-Score: -3.64 (Cap -4..+1) = AAA |
What is the price of ATYR shares?
Over the past week, the price has changed by +1.81%, over one month by +24.17%, over three months by +16.75% and over the past year by -76.77%.
Is ATYR a buy, sell or hold?
- StrongBuy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATYR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.4 | 384.4% |
| Analysts Target Price | 4.4 | 384.4% |
| ValueRay Target Price | 0.7 | -20% |
ATYR Fundamental Data Overview February 05, 2026
P/B = 1.1731
Revenue TTM = 190.0k USD
EBIT TTM = -77.7m USD
EBITDA TTM = -76.5m USD
Long Term Debt = 12.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.43m USD (from shortTermDebt, last quarter)
Debt = 12.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.21m USD (from netDebt column, last quarter)
Enterprise Value = 16.2m USD (94.1m + Debt 12.4m - CCE 90.2m)
Interest Coverage Ratio = -30.75 (Ebit TTM -77.7m / Interest Expense TTM -2.52m)
EV/FCF = -0.26x (Enterprise Value 16.2m / FCF TTM -63.0m)
FCF Yield = -387.8% (FCF TTM -63.0m / Enterprise Value 16.2m)
FCF Margin = -33.2k% (FCF TTM -63.0m / Revenue TTM 190.0k)
Net Margin = -39.5k% (Net Income TTM -75.1m / Revenue TTM 190.0k)
Gross Margin = unknown ((Revenue TTM 190.0k - Cost of Revenue TTM 35.1m) / Revenue TTM)
Tobins Q-Ratio = 0.15 (Enterprise Value 16.2m / Total Assets 106.7m)
Interest Expense / Debt = 1.03% (Interest Expense 127.0k / Debt 12.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -61.3m (EBIT -77.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.93 (Total Current Assets 93.0m / Total Current Liabilities 15.7m)
Debt / Equity = 0.15 (Debt 12.4m / totalStockholderEquity, last quarter 80.2m)
Debt / EBITDA = -0.08 (negative EBITDA) (Net Debt 6.21m / EBITDA -76.5m)
Debt / FCF = -0.10 (negative FCF - burning cash) (Net Debt 6.21m / FCF TTM -63.0m)
Total Stockholder Equity = 75.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -75.78% (Net Income -75.1m / Total Assets 106.7m)
RoE = -100.1% (Net Income TTM -75.1m / Total Stockholder Equity 75.0m)
RoCE = -88.85% (EBIT -77.7m / Capital Employed (Equity 75.0m + L.T.Debt 12.4m))
RoIC = -81.75% (negative operating profit) (NOPAT -61.3m / Invested Capital 75.0m)
WACC = 8.54% (E(94.1m)/V(106.4m) * Re(9.56%) + D(12.4m)/V(106.4m) * Rd(1.03%) * (1-Tc(0.21)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 28.04%
Fair Price DCF = unknown (Cash Flow -63.0m)
EPS Correlation: 79.66 | EPS CAGR: 90.73% | SUE: 4.0 | # QB: 1
Revenue Correlation: -48.53 | Revenue CAGR: -76.66% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=+0.006 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.56 | Chg30d=+0.036 | Revisions Net=-3 | Growth EPS=+31.7% | Growth Revenue=+2682.0%